



**PSN632408** 

**Catalog No: tcsc3191** 

| Available Sizes   |  |  |
|---|--|--|
| Size: 5mg   |  |  |
| Size: 10mg  |  |  |
| Size: 50mg  |  |  |
| Specifications  |  |  |
| <b>CAS No:</b> 857652-30-3  |  |  |
| Formula:<br>C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O <sub>4</sub> |  |  |
| Pathway:<br>GPCR/G Protein  |  |  |
| <b>Target:</b><br>GPR119  |  |  |
| Purity / Grade: >98%  |  |  |
| <b>Solubility:</b><br>10 mM in DMSO                                       |  |  |
| Observed Molecular Weight:  |  |  |

## **Product Description**

360.41

PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9 uM, respectively.





IC50 value: 5.6/7.9 uM (recombinant mouse/ human GPR119) [1]

Target: GPR119 agonist

Systemic administration of PSN632408 (30 mg/kgintraperitoneally) suppresses food intake, reduces weight gain, and white adipose tissue deposition in rats. GPR119 (previously designated SNORF25) is an orphan G protein-coupled receptor expressed predominantly in the pancreas and gastrointestinal tract in humans and in the brain, pancreas, and gastrointestinal tract in rodents. It mediates a reduction in food intake and body weight gain in rats upon treatment with oleoyl ethanolamide (OEA), an endogenous, potent agonist for PPAR $\alpha$ . These data suggest that PSN632408 may be useful as a therapeutic agent for the treatment of obesity.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!